GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Patients with Small Cell Lung Cancer, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability
Epistemonikos ID: d3cc76e5ea525e96733fcc657ef388c10c59eda2
First added on: May 09, 2024